About
About Us
Company Overview
Orinove Inc., is a pharmaceutical company focused on novel products for the treatment of unmet medical needs and serious diseases.
- ORIN1001 is a proprietary oral drug candidate for the treatment of cancer and IPF (idiopathic pulmonary fibrosis).
- ORIN1001 is poised to start Phase 2 clinical trials for the treatment of advanced solid tumors and metastatic breast cancer.
- Phase 1 dose escalation trials are complete in the US and China.
- ORIN1001 is currently treating patients with IPF in a Phase 1b clinical trial in the US.
- Our drug pipeline extends to other cancer types and serious diseases including, inflammation and neurodegenerative disease
Meet Our Leadership Team
News and Literature
Company News
- Company Mission: Solve unmet medical needs with innovative medicine
- R&D Focus: Novel medicines targeting the tumor microenvironment and ER Stress
- Clinical Development: ORIN1001, a First-in-Class IRE1α inhibitor, currently in Phase 2 trials in cancer and Phase 1b in IPF
- Leadership team: Drs. Qingping (Ted) Zeng, John Patterson and Stephanie Greene
